Nigella sativa in the Management of Type 2 Diabetes Mellitus: A Review of Contemporary Pharmacological Evidence and the Prophetic Medicine (Tibb al-Nabawi) Tradition
Year: 2026
Type: article
Abstract: Type 2 diabetes mellitus (T2DM) is a growing global health burden, and many patients use complementary agents alongside standard therapy. Nigella sativa L. (black seed, habbatu sawda) is among the most widely used of these, and it is prominent in the Prophetic medicine (Tibb al-Nabawi) tradition. The scientific and traditional literatures have rarely been examined together in a way that keeps their evidentiary standards distinct. This study aimed to critically appraise the preclinical and clinical evidence for N. sativa and its principal constituent thymoquinone (TQ) in T2DM, to examine how the Prophetic medicine tradition characterises black seed, and to assess where the two bodies of knowledge converge and diverge. An integrative narrative review was designed following SANRA quality criteria, with a search of PubMed, Scopus, Web of Science, and Embase for pharmacological literature, and a source-critical reading of authenticated hadith collections and classical medical texts for the traditional literature. Preclinical work consistently shows that N. sativa preparations and TQ improve glycaemic indices through several mechanisms. These include enhanced glucose-stimulated insulin secretion, reduced hepatic gluconeogenesis, improved peripheral insulin signalling, reduced intestinal glucose absorption, and attenuation of oxidative and inflammatory stress. Meta-analyses of randomised controlled trials, including those published in 2024–2026, report statistically significant reductions in fasting glucose and glycated haemoglobin (HbA1c), by about 0.4– 0.6 percentage points were reported in natural units, with no consistent effect on insulin or HOMA-IR, but trials are small, short, and heterogeneous in preparation, dose, and quality. The Prophetic tradition presents black seed as a broad-spectrum remedy and does not address T2DM specifically, so any link to diabetes is an interpretive extension. N. sativa is a promising adjunct, not a replacement, for standard T2DM care. The tradition supports cultural acceptability and a plausible prior for benefit, while the pharmacological evidence has to stand on its own methodological merits. Standardised preparations, larger and longer trials, pharmacokinetic work on TQ, and herb-drug interaction studies are priorities.
Language: English
Subfield: Complementary and alternative medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7230331926
